3077P Enfortumab vedotin with pembrolizumab (EVP) treatment outcomes in patients with histologic subtypes of advanced urothelial carcinoma: Analysis of the UNITE study
Year: 2025
Type: article
Source: Annals of Oncology
Authors: T. Jindal, C.Y. Jiang, O. Alhalabi, E. Oh, A. Jang, J. Bellmunt, H. Emamekhoo, C.J. Hoimes, M.A. Bilen, Y. Zakharia, S. Gupta, M. Milowsky, S. Shah, A. Basu, A. Tripathi, P. Grivas, J. Brown, I. Tsung, M.T. Campbell, V.S. Koshkin
Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, University of Michigan, Michigan Medicine, University Hospitals of Cleveland, Case Western Reserve University, Harvard University, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Duke Cancer Institute, Winship Cancer Institute, University of Iowa Hospitals and Clinics, Cleveland Clinic, University of North Carolina at Chapel Hill, Stanford Medicine, Stanford University, University of Alabama at Birmingham, UAB Medicine, City Of Hope National Medical Center, City of Hope, University of Washington, U-M Rogel Cancer Center, University of California San Francisco Medical Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415940081